{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:05:41Z","timestamp":1791921941198,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.xphs.2021.06.034","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T22:48:13Z","timestamp":1625179693000},"page":"247-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine"],"prefix":"10.1016","volume":"111","author":[{"given":"Karthik","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Kozminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Kohout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Wisniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Hargrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.06.034_bib0001","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","article-title":"Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products","volume":"298","author":"Amara","year":"1982","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.xphs.2021.06.034_bib0002","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol Rev"},{"key":"10.1016\/j.xphs.2021.06.034_bib0003","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.2994212","article-title":"Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide","volume":"229","author":"Amara","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.xphs.2021.06.034_bib0004","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/308746a0","article-title":"Isolation and characterization of human calcitonin gene-related peptide","volume":"308","author":"Morris","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2021.06.034_bib0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0167-0115(85)90194-6","article-title":"Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat","volume":"12","author":"Mulderry","year":"1985","journal-title":"Regul Pept"},{"issue":"42","key":"10.1016\/j.xphs.2021.06.034_bib0006","doi-asserted-by":"crossref","first-page":"21925","DOI":"10.1074\/jbc.M116.751362","article-title":"Receptor Activity-modifying Protein-directed G Protein Signaling Specificity for the Calcitonin Gene-related Peptide Family of Receptors","volume":"291","author":"Weston","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.xphs.2021.06.034_bib0007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","article-title":"RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2021.06.034_bib0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/313054a0","article-title":"Calcitonin gene-related peptide is a potent vasodilator","volume":"313","author":"Brain","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2021.06.034_bib0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.xphs.2021.06.034_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.xphs.2021.06.034_bib0011","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/head.13379","article-title":"History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) therapies: from translational research to treatment","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.xphs.2021.06.034_bib0012","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","article-title":"Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products","volume":"298","author":"Amara","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2021.06.034_bib0013","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0166-2236(85)90050-5","article-title":"Functional role of perivascular peptides in the control of cerebral circulation","volume":"8","author":"Edvinsson","year":"1985","journal-title":"Trends Neurosci"},{"issue":"19","key":"10.1016\/j.xphs.2021.06.034_bib0014","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.1021\/jm500364u","article-title":"Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine","volume":"57","author":"Bell","year":"2014","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.xphs.2021.06.034_bib0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0333102410388435","article-title":"BI 44370 TA, an Oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study","volume":"31","author":"Diener","year":"2011","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.xphs.2021.06.034_bib0016","first-page":"566","article-title":"Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment","volume":"10","author":"Recober","year":"2007","journal-title":"IDrugs"},{"issue":"2","key":"10.1016\/j.xphs.2021.06.034_bib0017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial","volume":"34","author":"Marcus","year":"2014","journal-title":"Cephalalgia"},{"key":"10.1016\/j.xphs.2021.06.034_bib0018","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/WCO.0000000000000438","article-title":"Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies","volume":"30","author":"Mitsikostas","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.xphs.2021.06.034_bib0019","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11916-015-0476-1","article-title":"TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine","volume":"19","author":"Walter","year":"2015","journal-title":"Current Pain Headache Rep"},{"issue":"7","key":"10.1016\/j.xphs.2021.06.034_bib0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11534920-000000000-00000","article-title":"CGRP receptor antagonists in the treatment of migraine","volume":"24","author":"Durham","year":"2010","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.xphs.2021.06.034_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543784.2015.960921","article-title":"CGRP antagonists and antibodies for the treatment of migraine","volume":"24","author":"Vecsei","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.xphs.2021.06.034_bib0022","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.xphs.2021.06.034_bib0023","first-page":"711","article-title":"Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine","volume":"10","author":"Tepper","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.xphs.2021.06.034_bib0024","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40259-017-0250-5","article-title":"CGRP monoclonal antibodies for migraine: rationale and progress","volume":"31","author":"Yuan","year":"2017","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.xphs.2021.06.034_bib0025","doi-asserted-by":"crossref","DOI":"10.1021\/jm970533r","article-title":"From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor","volume":"41","author":"Rist","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2021.06.034_bib0026","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT 1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltran","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xphs.2021.06.034_bib0027","doi-asserted-by":"crossref","first-page":"e01215","DOI":"10.1002\/brb3.1215","article-title":"CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis","volume":"9","author":"Han","year":"2019","journal-title":"Brain Behav"},{"issue":"2","key":"10.1016\/j.xphs.2021.06.034_bib0028","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/jm050613s","article-title":"Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor","volume":"49","author":"Lang","year":"2006","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.xphs.2021.06.034_bib0029","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1021\/jm8009298","article-title":"Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor","volume":"51","author":"Miranda","year":"2008","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.xphs.2021.06.034_bib0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/psc.1358","article-title":"Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists","volume":"17","author":"Yan","year":"2011","journal-title":"J Pept Sci"},{"issue":"6","key":"10.1016\/j.xphs.2021.06.034_bib0031","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in Migraine A comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"Tfelt-Hansen","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2021.06.034_bib0032","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nature Rev Drug Discov"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921003543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921003543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:35:49Z","timestamp":1758360949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921003543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0022354921003543"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.06.034","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}